HCP Resource Centre for REBLOZYL^®

WE ARE HERE TO SUPPORT YOU AND YOUR PATIENTS!

Feel free to download and review the materials in this library to learn more about REBLOZYL, along with patient tools to help you support your patients and their caregivers during their treatment with REBLOZYL. Check back from time to time – new materials will be added as they are released.

Discover the FIRST and ONLY erythroid maturation agent indicated for adults with:

• Transfusion-dependent anemia resulting from very low (ie, very low-) to intermediate-risk myelodysplastic syndromes (MDS) with ring sideroblasts who have failed or are not suitable for endogenous erythropoietin-based therapy*
• Red blood cell transfusion-dependent anemia associated with β-thalassemia*

REBLOZYL (luspatercept for injection) is indicated for:

• The treatment of adult patients with red blood cell (RBC) transfusion-dependent anemia associated with beta(β)-thalassemia.
• The treatment of adult patients with transfusion-dependent anemia requiring at least two RBC units over
  8 weeks resulting from very low- to intermediate-risk myelodysplastic syndromes (MDS) who have ring sideroblasts and who have failed or are not suitable for erythropoietin-based therapy.

Limitation of Use
REBLOZYL is an erythroid maturation agent. It is not indicated for use as a substitute for RBC transfusions in patients who require immediate correction of anemia.

No clinically meaningful change in liver iron concentration was observed in
β-thalassemia patients treated with REBLOZYL plus best supportive care (BSC) compared to patients treated with placebo plus BSC at 48 weeks.

*Comparative clinical significance is unknown.

Did you know?
The Patient Support Program for REBLOZYL is designed to help support you and your patients.
Contact us at 1-833-951-2482 between Monday and Friday
(8AM– 8PM EST)

Click on any resource to view or download

FILTER BY

• All (24)
• Myelodysplastic syndromes (MDS) (15)
• Product Monograph (1)
• Videos (3)
• Physician-directed (12)
• Nurse-directed (8)
• Patient-directed (2)
• Patient service program (PSP) (6)
• Risk Minimization tools (2)
• Beta-thalassemia (14)
• Product Monograph (1)
• Videos (3)
• Physician-directed (11)
• Nurse-directed (7)
• Patient-directed (2)
• Patient service program (PSP) (6)
• Risk Minimization tools (2)

ALL (24)

Product Monograph

Important information relating to contraindications, warnings, precautions, adverse reactions, interactions, dosing information, and conditions of clinical use of REBLOZYL as approved by Health Canada.

DOWNLOAD

Mechanism of action

Watch this video for a deep dive on how REBLOZYL works.

PLAY

MDS^‡ dosing and administration video

This dosing and administration video provides important information on dosing and administering REBLOZYL in your MDS patients.

PLAY

Beta-thalassemia^† dosing and administration video

This dosing and administration video provides important information on dosing and administering REBLOZYL in your Beta-thalassemia patients.

PLAY

Reconstitution instructional video

This instructional video demonstrates how to properly reconstitute REBLOZYL.

PLAY

Your REBLOZYL Overview – Myelodysplastic syndromes (MDS)^‡

For patients living with myelodysplastic syndromes, get a summarized and clear depiction of REBLOZYL mechanism of action, recommended dose, and safety profile and efficacy profile.

DOWNLOAD

Your REBLOZYL Overview – Beta-thalassemia^†

For patients living with beta-thalassemia, get a summarized and clear depiction of REBLOZYL mechanism of action, recommended dose, and safety profile and efficacy profile.

DOWNLOAD

Dose guide – Myelodysplastic syndromes (MDS)^‡

Download this resource designed to guide you through dosing and administering REBLOZYL to your patients living with myelodysplastic syndromes.

DOWNLOAD

Dose guide – Beta-thalassemia^†

Download this resource designed to guide you through dosing and administering REBLOZYL to your patients living with beta-thalassemia.

DOWNLOAD

MDS Quick Reference Guide – Myelodysplastic syndromes (MDS)^‡

Use this short guide when assessing if your patient living with myelodysplastic syndrome is a candidate for receiving REBLOZYL. Find the REBLOZYL dosing titration recommendations, including important dose modifications. If you are looking for complete recommended dose modifications, please see the MDS Dosing and Reconstitution Guide or the Product Monograph.

DOWNLOAD

Nurse guide – Myelodysplastic syndromes (MDS)^‡

Review this guide for detailed safety profile considerations and management of REBLOZYL therapy in your patients living with myelodysplastic syndromes.

DOWNLOAD

Nurse guide – Beta-thalassemia^†

Review this guide for detailed safety profile considerations and management of REBLOZYL therapy in your patients living with beta-thalassemia.

DOWNLOAD

Patient Support Program for REBLOZYL Guide – Myelodysplastic syndromes (MDS)^‡

Download this Patient Support Program slide deck to overview the services available to you and your patients living with myelodysplastic syndromes throughout the treatment journey with REBLOZYL.

DOWNLOAD

Patient Support Program for REBLOZYL Guide – Beta-thalassemia^†

Download this Patient Support Program slide deck to get an overview of the services available to you and your patients living with beta-thalassemia throughout the treatment journey with REBLOZYL.

DOWNLOAD

PSP Enrolment form – Myelodysplastic syndromes (MDS)^‡

Complete this form to register your patients living with myelodysplastic syndromes in the Patient Support Program. See the in-service slide deck for more information on how to use this form.

DOWNLOAD

PSP Enrolment form – Beta-thalassemia^†

Complete this form to register your patients living with beta-thalassemia in the Patient Support Program. See the in-service slide deck for more information on how to use this form.

DOWNLOAD

PSP Authorization to Inject form – Myelodysplastic syndromes (MDS)^‡

Complete this form for your patient living with myelodysplastic syndromes per your preference indicated in the Enrolment form, after a period of 8 dosing cycles (24 weeks), or upon a change of dose. See the in-service slide deck for more information on how to use this document.

DOWNLOAD

PSP Authorization to Inject form – Beta-thalassemia^†

Complete this form for your patient living with beta-thalassemia per your preference indicated in the Enrolment form, after a period of 8 dosing cycles (24 weeks), or upon a change of dose. See the in-service slide deck for more information on how to use this document.

DOWNLOAD

PSP Post-Injection Report form – Myelodysplastic syndromes (MDS)^‡

Complete this form for your patient living with myelodysplastic syndromes after each REBLOZYL injection at a Program-affiliate private clinic. See the in-service slide deck for more information on how to use this form.

DOWNLOAD

PSP Post-Injection Report form – Beta-thalassemia^†

Complete this form for your patient living with beta-thalassemia after each REBLOZYL injection at a Program-affiliate private clinic. See the in-service slide deck for more information on how to use this form.

DOWNLOAD

Risk Minimization Card

This Risk Minimization Tool is designed to help your patients remember that REBLOZYL should not be taken if they are pregnant or breast-feeding, or could become pregnant and are not using an effective method of birth control.

DOWNLOAD

Prescriber checklist

This Risk Minimization Tool provides important information for healthcare providers prescribing REBLOZYL to women of childbearing potential.

DOWNLOAD

MDS^‡ Patient Guide

This guide is designed to help your patients understand more about their treatment with REBLOZYL. If they are living with myelodysplastic disease syndromes (MDS), here they can find information about supply and delivery of their medication, lifestyle tips, and reimbursement navigation.

DOWNLOAD

Beta-thalassemia^† Patient Guide

This guide is designed to help your patients understand more about their treatment with REBLOZYL. If they are living with beta-thalassemia, here they can find information about supply and delivery of their medication, lifestyle tips, and reimbursement navigation.

DOWNLOAD

Prefer printed copies of your REBLOZYL resources? Please send us an email request at Reblozyl.tools@bms.com.

Visit Patient Resource Centre